ASAN FOUNDATION

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1989-06-23

Employees: 501

Market Cap: -

Website: https://ails.amc.seoul.kr

Clinical Trials

Study of Gastroduodenal Metallic Stent vs Gastrojejunostomy

Phase 3

Conditions: Gastric Cancer

Interventions: Procedure: gastrojejunostomy
Device: gastroduodenal stent placement

First Posted Date: 2016-05-27

Last Posted Date: 2016-05-27

Lead Sponsor: Asan Medical Center

Target Recruit Count: 92

Registration Number: NCT02784470

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors

Phase 4

Conditions: Non Functioning Pancreatic Endocrine Tumor

Interventions: Biological: Chromogranin A

First Posted Date: 2016-05-03

Last Posted Date: 2016-05-03

Lead Sponsor: Asan Medical Center

Target Recruit Count: 111

Registration Number: NCT02759718

Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy

Phase 4

Completed

Conditions: Benign Neoplasm of Body of Pancreas
Benign Neoplasm of Tail of Pancreas

Interventions: Device: 3-dimensional distal pancreatectomy
Device: 2-dimensional distal pancreatectomy

First Posted Date: 2016-05-02

Last Posted Date: 2016-05-02

Lead Sponsor: Asan Medical Center

Target Recruit Count: 60

Registration Number: NCT02757690

Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

Phase 2

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: bendamustine, rituximab

First Posted Date: 2016-04-27

Last Posted Date: 2016-04-27

Lead Sponsor: Asan Medical Center

Target Recruit Count: 22

Registration Number: NCT02753062

Locations: 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine

First Posted Date: 2016-04-22

Last Posted Date: 2019-11-25

Lead Sponsor: Asan Medical Center

Target Recruit Count: 44

Registration Number: NCT02749136

Locations: 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma

Phase 2

Conditions: Treatment Response
Feasibility
Adverse Events

Interventions: Procedure: Photodynamic therapy

First Posted Date: 2016-03-31

Last Posted Date: 2016-04-14

Lead Sponsor: Asan Medical Center

Target Recruit Count: 32

Registration Number: NCT02725073

Locations: 🇰🇷
Do Hyun Park, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors (GISTs)

Interventions: Drug: Imatinib Mesylate

First Posted Date: 2016-03-18

Last Posted Date: 2023-01-04

Lead Sponsor: Asan Medical Center

Target Recruit Count: 51

Registration Number: NCT02712112

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Phase 4

Completed

Conditions: Mitral Valve Insufficiency
Left Ventricular Dysfunction

Interventions: Drug: LCZ696
Drug: Valsartan

First Posted Date: 2016-02-22

Last Posted Date: 2018-01-09

Lead Sponsor: Asan Medical Center

Target Recruit Count: 118

Registration Number: NCT02687932

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Yonsei University Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 1 locations

Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Phase 2

Terminated

Conditions: Neutropenia
Febrile Neutropenia
Breast Cancer

Interventions: Drug: Peg-filgrastim
Drug: Filgrastim

First Posted Date: 2016-02-18

Last Posted Date: 2020-07-31

Lead Sponsor: Asan Medical Center

Target Recruit Count: 22

Registration Number: NCT02685111

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)

Phase 4

Conditions: Cervical Intraepithelial Neoplasia
Cervical Cancer

Interventions: Drug: Tachosil

First Posted Date: 2015-12-14

Last Posted Date: 2017-05-31

Lead Sponsor: Asan Medical Center

Target Recruit Count: 268

Registration Number: NCT02629510

Locations: 🇰🇷
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy